Article ID Journal Published Year Pages File Type
2785958 International Journal of Developmental Neuroscience 2014 8 Pages PDF
Abstract

•The classic MCAO model is applied to study the neuroprotection of sevoflurane postconditioning.•The expression of Nrf2 and the Nrf2-binding activity to ARE are upregulated obviously by administration of sevoflurane postconditioning.•The neuroprotection of sevoflurane postconditioning is mediated by the PI3K/Akt pathway involving Nrf2.

Oxidative damage plays a critical role in many diseases of the central nervous system. This study was conducted to determine the molecular mechanisms involved in the putative anti-oxidative effects of sevoflurane against experimental stroke. Focal cerebral ischemia was performed via 1 h of middle cerebral artery occlusion followed by reperfusion. At the onset of reperfusion, rats were subjected to postconditioning with sevoflurane or without sevoflurane for 1 h. Neurological deficit score was assessed at different time points after reperfusion. Cerebral infarct volume, oxidative stress level and the binding activity of Nrf2 to antioxidant response element were assessed, meanwhile the expression of nuclear factor-erythroid 2-related factor 2 (Nrf2), quinine oxidoreductase 1 (NQO1), protein kinase B (Akt) and phosphor-Akt was examined by Western blot at 72 h after reperfusion. Sevoflurane postconditioning administration significantly reduced neurological deficit score, infarct volume and oxidative stress levels, while increased the expression of phosphorylation Akt, NQO1, Nrf2 and the binding activity of Nrf2 to ARE in middle cerebral artery occlusion rats. These neuroprotective effects were all suppressed by LY294002, a selective PI3K blocker. Taken together, these findings provided evidence that sevoflurane postconditioning protects brain against ischemic/reperfusion injury, and this neuroprotective effect involves the Akt/Nrf2 pathway.

Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Developmental Biology
Authors
, , , , , , , ,